CMS Open Payments · Program Year 2024
Terumo BCT, Inc.
Terumo BCT, Inc. reported $777,970.93 across General Payments, Research, and Ownership to 32 physicians and teaching hospitals across 37 transactions.
- $778.0K Above-median payer
- All-tracks total
- 37 Below-median volume
- Transactions
- 32 Below-median reach
- Recipients
- −$21.2K
- General Payments vs PY2023
Terumo BCT, Inc. reported $777,970.93 across all CMS Open Payments tracks (General + Research + Ownership) to 32 physicians and teaching hospitals in Program Year 2024 - ranking #678 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $78,358.18, averaging $24.3K per recipient.
How Terumo BCT, Inc.'s $778.0K all-tracks total breaks down
Terumo BCT, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
22/100
Total payments
F
17/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer terumo-bct-inc Terumo BCT, Inc.
$778.0K · #678/1,925 · 0.0% industry · PY2024
- TOT $778.0K
- RANK #678
- SHARE 0.0%
- TXN 37
- RCP 32
- CAT 4
- GEN $78.4K
- ΔGEN −$21.2K
- TOP1 68.3%
- PY 2024
Volume peers
Nearest volume peer: Itamar Medical Inc ($778.2K)
Terumo BCT, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Terumo BCT, Inc.'s CMS-reported General Payments decreased by $21.2K (−21.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: TERUMO BCT, INC.PY2023: TERUMO BCT, INC.PY2024: Terumo BCT, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $99,598.45
- PY2024
- $78,358.18
What the Data Shows for Terumo BCT, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Terumo BCT, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $65.8K, accounting for 84.0% of this company's General Payments and 13 transactions.
General Payment Breakdown by Type
"Consulting Fee" leads Terumo BCT, Inc.'s 4-category general-payment breakdown at $65.8K, 84.0% of the reported total.
Terumo BCT, Inc. reports 4 general-payment categories - the top three are Consulting Fee (84.0%), Compensation for Services Other Than Consulting (14.3%), and Food and Beverage (1.0%). The remaining 1 category make up 0.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Terumo BCT, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $65.8K | 13 | 84.0% |
| Compensation for Services Other Than Consulting | $11.2K | 3 | 14.3% |
| Food and Beverage | $778.18 | 15 | 1.0% |
| Grant | $500.00 | 1 | 0.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $75,000.00 (95.7%) of $78,358.18 in this company's General Payments records across 20 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Terumo BCT, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Ira D Davis
$53,500.00 across 10 reported transactions
- 2
Tina S Ipe
$7,400.00 across 1 reported transactions
- 3
Miguel R. Abboud
$5,530.00 across 1 reported transactions
- 4
Charles Knudson
$4,510.00 across 1 reported transactions
- 5
Robert W Maitta
$4,060.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Terumo BCT, Inc.'s spend rank (#678 of 1,925, top 35% by spend) and concentration rank (#382 of 1,838, top 21% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Elekta Limited : $1.3K total payments, HHI 4913
- Innova Vascular Inc. : $11.1K total payments, HHI 4911
- Austin Medical Ventures Inc : $204.6K total payments, HHI 4898
- Dentium USA : $63.0K total payments, HHI 4887
- Novavax Inc : $146.8K total payments, HHI 4878
- D.T. Davis Enterprises, Ltd : $36.4K total payments, HHI 4874
- Terumo BCT, Inc. (this company) : $78.4K total payments, HHI 4865
- ETS Wound Care LLC : $260.4K total payments, HHI 4864
- Biobeat USA Inc. : $11.6K total payments, HHI 4862
- Remington Medical, Inc. : $61.7K total payments, HHI 4851
- Darco International, Inc. : $8.5K total payments, HHI 4848
- Uromedica, Incorporated : $149.1K total payments, HHI 4832
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Terumo BCT, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Terumo BCT, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Terumo BCT, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
LinkBio Corp
Acessa Health Inc.
Affordable Pharmaceuticals, LLC
Kalitec Direct LLC
Dr.Reddy's Laboratories,Inc.
Put this to use
Terumo BCT, Inc. ranks #678 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Terumo BCT, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.